ImetelChat

True, good point.
Tangentially, Bluebird treatment got slapped with a box Warning. To state the obvious, Not looked on positively.

Nice, extended follow-ups and breakout of subgroup (using IPSS, prognostic scoring system).

Let’s see if this Phase III extended data leads to a Plenary…

I think it’s sooner rather than later biotechs are going to implement AI to find potential optimizations to their drugs (molecules) as well as analyzing combinations , etc etc etc…. Probably another reason why the global giants have a huge advantage with their IP. I would gather that company announc...

Like every major featured article in a top tier medical journal, a prominent physician is asked to comment. I did "buy" 24 hour access to the comments by Dr. Patnaik of the Mayo in Rochester. I am sure I had to agree not to reproduce it so I will just summarize a few points. Dr. Patnaik summarized ...

Ryan, I did not mean to cast doubt on your ability or anyone else’s to appreciate the current presentation of the Imetelstat data. I was merely sharing my own reaction to my first subscription to the NEJM as a first year, first day 22 year old medical student. No aspersions or judgements were meant...

The commentary that accompanies the Lancet article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02187-6/fulltext# takes us back to the Mayo Clinic in Rochester Minn. I hope Dr. Tefferi is able to find some satisfaction in seeing a close colleague of his bring further recognit...

rccola335 wrote: ↑

Sun Dec 03, 2023 11:23 pm

https://x.com/Dr_AmerZeidan/status/1731 ... 69038?s=20

And the best response of all;) !

When the data is so amazing, but of course very difficult to comprehend on a basic (normal people like us) level, just post a “:)”

rccola335 wrote: ↑

Sun Dec 03, 2023 11:22 pm

https://x.com/MrinalPatnaik/status/1730 ... 71507?s=20

“Ready for Prime Time”

There it is, the overnight success story that was 12 years in the making.

rccola335 wrote: ↑

Sun Dec 03, 2023 11:22 pm

https://x.com/VidhyaMurthy1/status/1730 ... 35304?s=20

Nice, ‘#MDS Gurus from around the world’ pretty much says it all
(Quoted the wrong tweet, it was Dr. Madanat’s tweet that says this.)

Ouch. Getting roasted.
Wonder if that’s worth over a million in salary and options in that time

He still has time to come through!

The Gong didn’t work :roll: I like seeing the background of new hires. Not sure I’m too worried about someone who has probably become Dr Rizo’s friend / confidant over the years. As refernced, ai further that an exodus of science experts (not worried about the CLO or CFO) from the company. Noting th...

So no one is buying into the New Molecular Entity thing I see.

Me neither.

I would say that every time there is a modification to this trial, a lot of flags are raised and flown, a lot of cheers and exuberance… but, I agree that this is a non-issue. It’s been stated that this is part and parcel with an application for marketing approval with the EMA. If a new trial were be...

Such valid conjecture there.

From the data, I would be absolutely stunned/shocked absolutely flummoxed, choose your word… if Imetelstat is not approved for marketing authorization by the FDA…
— But from the vibes and the Geron share price, I wouldn’t be surprised in the least <— go figure.

Notice this is not Geron PR involved in this press, articles and news clips, in Australia. Dr. Lane and Dr. Claudia B are independently interacting with journalists, who find their discoveries news worthy. That is their right as industry experts, but it is clear Geron is not involved in this ‘public...

So true. Her quote from the article I posted (“Dr Lane speaks”) definitely shows her excitement about reaching this point in what clearly was/is a long and winding road: Lead author Dr Claudia Bruedigam from QIMR Berghofer said the research involved years of tireless work by an international researc...

Share price is controlled by buyers and sellers. There is no entity or entities “controlling” the stock price behind the proverbial curtain. Take notice that the management times every, single private share offering or intent to offer… with good news.
No need to respond LWS. Please don’t.

Well you were incorrect about the current funds, however, have been pretty right about the clear disdain for individual shareholders by management. Once again, they drop a stink bomb on what otherwise would have been catalyst-creating amazing news. The agreement for $100M at the market authorized sh...

“Having this extra weapon in our arsenal would create so much opportunity particularly in combining this drug, and others like it, with existing treatments like chemotherapy and other novel cancer therapies," Professor Lane said. "This could transform the way we think about treating patients with bl...

Current cash on balance sheet is a lot higher than the guesses / estimates made on this board in the past weeks. Exercise of warrants has bolstered.